Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Iv Trial To Assess The Effectiveness Of Apixaban Compared With Usual Care Anticoagulation In Subjects With Non-valvular Atrial Fibrillation Undergoing Cardioversion

NCT02100228 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT02100228
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02100228 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Iv Trial To Assess The Effectiveness Of Apixaban Compared With Usual Care Anticoagulation In Subjects With Non-valvular Atrial Fibrillation Undergoing Cardioversion
Lead sponsor
Pfizer
Phase
Phase 4
Overall status
Completed
Start date
July 14, 2014
Completion date
February 8, 2017
Enrollment
1,500 (actual)
Sites
165

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation